ACS Medicinal Chemistry Letters· 2026Q1
Structure-Based Drug Design of Quinoline CYP8B1 Inhibitors for the Potential Treatment of Metabolic Disease
- 0citations
- Q1SCImago
- 2026year
Short summary
Structure-based drug design yielded compound 9, a CYP8B1 inhibitor with improved metabolic stability and in vivo efficacy in mice, offering a promising therapeutic avenue for metabolic diseases like NAFLD and T2D.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openPharmacologyPharmacology, Toxicology and Pharmaceutics